Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM (CYNK001GBM01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04489420
Recruitment Status : Recruiting
First Posted : July 28, 2020
Last Update Posted : October 12, 2020
Sponsor:
Information provided by (Responsible Party):
Celularity Incorporated

Brief Summary:
This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy for the systemic cohort (IV) (intravenous). The intratumoral cohort (IT) will not be giving lymphodepletion. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating recurrent glioblastoma multiforme.

Condition or disease Intervention/treatment Phase
Astrocytoma, Grade IV Giant Cell Glioblastoma Glioblastoma Multiforme Cyclophosphamide Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-infective Agents Analgesics, Non-narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Biological: CYNK001-IV Biological: CYNK001-IT Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: 2 modalities Systemic vs Intratumoral. For systemic experimental: Cyclophosphamide at Day -3 followed by CYNK-001. On Days 0, 7, and 14. Experimental IntraTumoral, Ommaya placement surgery 7 days prior to CYNK-001 administrations at Days 0, 7 and 14
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults With Recurrent Glioblastoma Multiforme (GBM)
Actual Study Start Date : October 1, 2020
Estimated Primary Completion Date : September 1, 2023
Estimated Study Completion Date : February 1, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intravenous IV ( Recurrent and Surgical ) GBM
Cohort 1A ( recurrent GBM) will receive CYNK-001 at a dose of 1.2 x 10^9 cells intravenous ( IV) on Days 0, 7, and 14 and will include up to 6 subjects. The subjects will be followed for a 42 day DLT period from the initial CYNK-001 infusion (or 28 days after the last dose). No other treatment interventions are planned between the last day of CYNK-001. In the event of DLTs, Cohort 1C ( recurrent GBM dose-De escalation) will receive CYNK-001 at a dose of 600 x 10^6 cells (IV) on Days 0, 7, 14, and will include up to 6 subjects who will be followed for a 42-day DLT period from the initial CYNK-001 infusion (or 28 days after the last dose. Cohort 1B (surgical cohort) will receive CYNK-001 at the maximum safe dose (MSD) (either 1.2x10^9 cells or 600x10^6 cells) (IV) at Days 0, 7, 14, and will include up to 6 subjects. The tumor resection surgery will be performed after the last CYNK-001 infusion during the DLT period.
Biological: CYNK001-IV
Planned Starting dose dor IV 1.2x10^9 cells/dose
Other Name: CYNK-001 dose level 1 for IV

Experimental: Intratumoral IT ( Recurrent and Surgical ) GBM)
The cohort 2A or cohort 2C (recurrent GBM) IT route of administration can be started only after the safety results were acceptable from the completion of cohort 1A or Cohort 1C (IV route of administration). The Treatment Period for the IT cohorts will begin with having the Ommaya catheter placement per institutional policy, which is planned to occur within one week prior to the CYNK-001 administration on Day 0. Cohort 2A will be treated with CYNK-001 IT at 200 x 10^6 ± 50 x 10^6 cells IT on Day 0, 7 and 14 includes up to 6 recurrent GBM subjects Cohort 2C ( dose de-escalation) will be treated with CYNK-001 200 x 106 ± 50 x 106 cells IT on Day 0, and Day 7 ( only two days dosing) and include up to 6 recurrent GBM subjects. Cohort 2B ( the surgical IT cohort) will be treated with CYNK-001 at the maximum safe dose ( MSD) (either 200 x 10^6 ± 50 x 10^6 cells on Days 0, 7 and 14 or at 200 x 10^6 ±50x10^6 cells on Days 0 and 7) and include up to 6 surgical GBM subjects
Biological: CYNK001-IT
Planned starting dose for IT 200 x10^6 +/- 50 x10^6 cells dose
Other Name: CYNK-001 dose level 2 for IT




Primary Outcome Measures :
  1. Number of Participants who experienced a Dose-Limiting Toxicity (DLT) [ Time Frame: Day 42 ]
    Defined as the maximum dose safely administered intravenously or Intratumoral for the treatment of patients with GBM.

  2. Adverse Events (AEs) [ Time Frame: 1 year ]
    Defined as the number and Severity of Adverse Events


Secondary Outcome Measures :
  1. Overall Response Rate [ Time Frame: 1 year ]
    Defined as the proportion of subjects with best overall response of either complete response (CR) or partial response (PR)

  2. Duration of Response Rate [ Time Frame: 1year ]
    Defined as duration from first observation of partial response (PR) or better to the date of disease progression per RANO criteria

  3. Progression-free survival [ Time Frame: 1year ]
    Defined as date of the first CYNK-001 infusion to the date of disease progression per RANO Response Criteria or death (regardless of cause of death), whichever comes first

  4. Time to porgression [ Time Frame: 1year ]
    Defined as the date of the first CYNK-001 infusion to the date of disease progression per RANO Response Criteria, with deaths from causes other than progression censored

  5. Overall Survival [ Time Frame: 1year ]
    Defined as the date of the first CYNK-001 infusion to the date of death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed glioblastoma multiforme (GBM) and are at first or second relapse.
  2. ≥ 18 years of age
  3. Have measurable disease of at least one solitary lesion with a dimension between 1 cm and 5 cm according to RANO
  4. Karnofsky performance status (KPS) ≥ 60
  5. Adequate organ function defined by laboratory values as follows: Creatinine < 140 µmol/L (1.6 mg/dL); if borderline, the creatinine clearance ≥40 mL/min, Bilirubin < 20% above the upper limit of normal, AST and ALT ≤ 2.5 the upper limit of normal.
  6. Absolute Neutrophil count baseline (ANC) ≥1500 cells/uL, Hemoglobin baseline ≥ 9.0 g/dL and Platelets baseline ≥ 100,000 cells/uL prior to the start of study treatment.
  7. Female of childbearing potential (FCBP) must not be pregnant and agree to not becoming pregnant for at least 42 days following the start of the treatment.
  8. Patients with HIV/AIDs are eligible if they have not had an opportunistic infection within the past 12 months
  9. Patients with chronic HBV infection or patients with current or a history of HCV infection are allowed if:

    1. have an HBV viral load below the limit of quantification and be on viral suppressive therapy
    2. have current HCV infection, they should be on concurrent HCV treatment and the HCV viral load must be below the limit of quantification
    3. have a history of HCV infection should have completed curative antiviral treatment and require HCV viral load below the limit of quantification

Exclusion Criteria:

  1. Had prior radiation therapy within 12 weeks of screening MRI unless there is unequivocal histological confirmation of tumor progression
  2. Subjects on growth factors therapy with less than 4 weeks washout period (for short-acting growth factors, such as G-CSF, GM-CSF 5-day wash-out for longer-acting factors (such as Neulasta) 10 days
  3. Radiotherapy, chemotherapy, or other investigational agents within 4 weeks
  4. Prior cellular or gene therapy at any time
  5. Clinical or laboratory signs for immunodeficiency or under immunosuppressive medication or steroids greater than15 mg prednisone or equivalent per day
  6. History of malignancy, other than GBM, unless the subject has been free of disease for > 3 years from the date of signing the ICF. Exceptions include the following noninvasive malignancies: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)
  7. Active autoimmune disease other than controlled connective tissue disorder or those who are not on active therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04489420


Contacts
Layout table for location contacts
Contact: Maha Rizk, BS 908-845-4356 maha.rizk@celularity.com
Contact: Kris Grzegorzewski, MD 908-845-4264 Kris.Grzegorzewski@celularity.com

Locations
Layout table for location information
United States, Texas
The Univeristy of Texas MD ANderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Nazanin Majd    713-792-1281    NKMajd@mdanderson.org   
Contact: Be-Lian Pei    713-792-8560    BPei@mdanderson.org   
Principal Investigator: Nazanin Majd, MD, PhD         
Sponsors and Collaborators
Celularity Incorporated
Investigators
Layout table for investigator information
Study Director: Kris Grzegorzewski, MD Celularity inc.
Layout table for additonal information
Responsible Party: Celularity Incorporated
ClinicalTrials.gov Identifier: NCT04489420    
Other Study ID Numbers: CYNK001-GBM-001
First Posted: July 28, 2020    Key Record Dates
Last Update Posted: October 12, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Celularity Incorporated:
CYNK-001
Glioblastoma Multiforme
Grade IV Astrocytoma
allogeneic
allogeneic stem cell
GBM
cell therapy
Cyclophosphamide
recurrent GBM
recurrent Glioblastoma Multiforme
primary and secondary recurrent GBM
NK cells
natural killer cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue